Korro Bio, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
KRRO$14.96+1.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(amounts in thousands, except share and par value amounts)
| September 30,2026 | December 31,2025 | |
|---|---|---|
| Assets: | ||
| Current assets: | ||
| Cash and cash equivalents | $40,215 | $21,824 |
| Short-term marketable securities | 64,779 | 53,332 |
| Accounts receivable | — | 969 |
| Prepaid expenses and other current assets | 3,941 | 6,247 |
| Total current assets | 108,935 | 82,372 |
| Property and equipment, net | 7,244 | 8,164 |
| Operating lease right-of-use assets | 7,333 | 8,058 |
| Restricted cash, net of current portion | 2,409 | 2,409 |
| Long-term marketable securities | 19,829 | 10,031 |
| Other non-current assets | 2,370 | 2,472 |
| Total assets | $148,120 | $113,506 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $3,296 | $1,651 |
| Accrued expenses and other current liabilities | 5,544 | 7,614 |
| Operating lease liabilities, current portion | 3,073 | 2,672 |
| Deferred revenue, current portion | 3,010 | — |
| Total current liabilities | 14,923 | 11,937 |
| Operating lease liabilities, net of current portion | 38,450 | 40,814 |
| Deferred revenue, net of current portion | 4,825 | 7,835 |
| Other non-current liabilities | 1,548 | 1,481 |
| Total liabilities | 59,746 | 62,067 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized at September 30, 2026 and December 31, 2025; no shares issued and outstanding at September 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value; 200,000,000 shares authorized at September 30, 2026 and December 31, 2025; 14,725,646 shares and 9,417,295 shares issued at September 30, 2026 and December 31, 2025, respectively; 13,725,646 shares and 9,417,295 shares outstanding at September 30, 2026 and December 31, 2025, respectively | 14 | 9 |
| Additional paid-in capital | 540,720 | 435,064 |
| Treasury stock, at cost, 1,000,000 shares held at September 30, 2026 and no shares held at December 31, 2025 | (12,120) | — |
| Accumulated other comprehensive (loss) income | (305) | 212 |
| Accumulated deficit | (439,935) | (383,846) |
| Total stockholders’ equity | 88,374 | 51,439 |
| Total liabilities and stockholders' equity | $148,120 | $113,506 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.